GLUCOSAFE 2 - A New Tool for Nutritional Management and Insulin-therapy in the Intensive Care Unit (ICU)
Critical Illness, Energy Supply; Deficiency, Severe, Protein Deficiency
About this trial
This is an interventional treatment trial for Critical Illness focused on measuring Nutrition management, Glycaemia control, ICU, Software, Critical illness, Insulin-therapy, Critically ill patients, Blood glucose control
Eligibility Criteria
Inclusion Criteria:
All patients ≥ 18 years admitted to the ICU with
- An expected length of stay ≥ 72h
- At least 1 blood glucose (BG) measurement ≥10 mmol/l or 2 BG measurement ≥ 8.5 mmol/l
- Informed Consent signed by the subject/ legal representative, except for patients in the historical control group
Exclusion Criteria:
- Lack of legal consent or consent withdrawn, except for patients in the historical control group
- Pregnant or breast feeding
- Diabetic ketoacidosis or hyperosmolar state
- Oral feeding
- Fulminant hepatic failure
- Medically contraindicated to receive rapidly acting insulin by intravenous (iv) infusion or iv injection
Sites / Locations
- Hôpitaux Universitaire de GenèveRecruiting
- Service of Intensive Care, Geneva University Hospital,Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Other
GLUCOSAFE 2
Local protocol control group
Historical control group
Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
Retrospective data with standard care before the beginning of the pilot study in order to minimize the "cross-over" effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time.